Le Lézard
Classified in: Health, Science and technology
Subjects: SLS, ACC

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT FEBRUARY 2024


Zinzino group revenue increased with a total of 25 %, compared with the previous year.

GOTHENBURG, Sweden, March 5, 2024 /PRNewswire/ -- The revenue in February for Zinzino's sales markets increased by 27 % and amounted to SEK 138.7 (109.6) million. Faun Pharma's external sales increased by 11 % and amounted to SEK 9.7 (8.7) million. Overall, the Group increased revenues by 25 % to SEK 148.4 (118.3) million compared with the previous year.

Accumulated revenue for January ? February 2024 increased by 20 % to SEK 297.4 (247.8) million.

Revenues were distributed as follows:

Regions,MSEK

24-Feb

23-Feb

Change

YTD 2024

YTD 2023

Change

The Nordics

22.2

23.2

-4 %

45.1

46.8

-4 %

Central Europe

36.7

26.9

36 %

77.6

55.4

40 %

East Europe

29.9

25.2

19 %

61.7

58,0

6 %

South & West Europe

24.6

14.4

71 %

46.6

30.3

54 %

The Baltics

8.3

6.1

36 %

16.3

13.4

22 %

North America

12.2

6.3

94 %

22.5

12.6

79 %

Asia-Pacific

3.6

6.5

-45 %

7.6

11.1

-32 %

Africa

1.2

1,0

20 %

2.2

2.4

-8 %

Zinzino

138.7

109.6

27 %

279.6

230.0

22 %

Faun Pharma

9.7

8.7

11 %

17.8

17.8

0 %

Zinzino Group

148.4

118.3

25 %

297.4

247.8

20 %

 

Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Turkey
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge: [email protected]

Certified Adviser: Carnegie Investment Bank AB (publ)

The following files are available for download:

https://mb.cision.com/Public/10976/3940666/8719ab7690b865c2.pdf

2402 Pressrelease Salesreport EN


These press releases may also interest you

at 07:00
To mark National Hospice Palliative Care Week, the Quebec Coalition for Palliative Care Access (the Coalition) is proud to celebrate the positive impact of palliative care on the well-being of people with life-limiting illness. Palliative care is...

at 06:00
A native born and trained Brazilian oncologist is in the forefront of a new era in the treatment of cancer patients with cutting edge proton therapy medical technology developed in Israel by P-Cure. "It is my dream to be able to bring the P-Cure...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO...

4 mai 2024
Women's Heart Health Month is recognized every May and is focused on raising awareness about cardiovascular health among women. It aims to educate women about the risks, symptoms, and prevention of heart disease, which is the leading cause of death...

4 mai 2024
RaySearch Laboratories AB (publ) and C-RAD are pleased to announce a collaboration agreement, aiming at jointly developing innovative solutions and products to enhance the quality of radiation therapy. The focus of the collaboration is to...



News published on and distributed by: